Long-acting cabotegravir and rilpivirine in people with HIV and cancer: Virological eligibility and DDI considerations.
- DOI
- 10.1002/bcp.70819
- Published
- 2026 Sep 10
- Container
- British journal of clinical pharmacology
- Publisher
- Not recorded
- Open access
- unknown
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1002/bcp.70819,
title = {Long-acting cabotegravir and rilpivirine in people with HIV and cancer: Virological eligibility and DDI considerations.},
author = {Gervasoni C and Cattaneo D and Dalu D and Cossu MV and Giacomelli A and Oreni L and Pozza G and Matone M and Fasola C and Perno CF and Gori A and La Verde N and Ridolfo AL},
year = {2026},
journal = {British journal of clinical pharmacology},
doi = {10.1002/bcp.70819},
url = {https://doi.org/10.1002/bcp.70819}
}RIS
TY - JOUR TI - Long-acting cabotegravir and rilpivirine in people with HIV and cancer: Virological eligibility and DDI considerations. AU - Gervasoni C AU - Cattaneo D AU - Dalu D AU - Cossu MV AU - Giacomelli A AU - Oreni L AU - Pozza G AU - Matone M AU - Fasola C AU - Perno CF AU - Gori A AU - La Verde N AU - Ridolfo AL PY - 2026 JO - British journal of clinical pharmacology DO - 10.1002/bcp.70819 UR - https://doi.org/10.1002/bcp.70819 ER -
APA
C, G., D, C., D, D., MV, C., A, G., L, O., G, P., M, M., C, F., CF, P., A, G., N, L. V., & AL, R. (2026). Long-acting cabotegravir and rilpivirine in people with HIV and cancer: Virological eligibility and DDI considerations.. British journal of clinical pharmacology. https://doi.org/10.1002/bcp.70819
Source records
- pubmed · retrieved 2026-09-26T00:04:06.174Z